Lifecode
SVBio rebranded as Lifecode, Inc., focusing on the genetic basis of human disease, particularly in oncology.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
Related Content
Lifecode, Inc., which previously operated as Silicon Valley Biosystems (SVBio), is a clinical laboratory focused on the application of genomic medicine, particularly within oncology. The company was rebranded from SVBio to Lifecode in January 2015 and was later acquired by MedGenome in a merger/acquisition deal dated February 2016. As a venture-backed entity, Lifecode secured funding from notable investors including Sequoia Capital and The Mayo Clinic, reflecting a strong foundation in both technology and clinical science.
The company was established by a team with deep expertise in computational biology, data science, and molecular biology. The founding members include Sivan Bercovici, Ph.D. (CTO), Eugene Fratkin, Ph.D. (Senior VP of Research & Development), Dietrich Stephan, Ph.D. (Scientist in Chief), and Helen Wang, M.S. (Head of Curation & Quality), with Chris Rivest serving as CEO. This collective background underscores the firm's direction in translating complex genomic data into actionable clinical insights.
Lifecode's primary business revolves around providing molecular information to improve patient outcomes. The company operates in the clinical genomics market, serving physicians by making complex sequencing information clinically relevant. Its business model centers on offering advanced laboratory services. As a CAP-accredited and CLIA-certified clinical laboratory, it is equipped to handle high-complexity molecular tumor profiling. Revenue is generated by providing these specialized testing services to healthcare providers. The company aimed to address the challenge of accurately interpreting the vast amount of genomic data produced by next-generation sequencing (NGS).
The core service offered by Lifecode was the Pan Cancer Somatic Panel. This assay was an NGS-based tumor profile designed to analyze and interpret genomic and therapeutic data for patients with cancer. The service provided patient-specific molecular information intended to be concise, accurate, and actionable for oncologists. By combining clinical genomics with big data analysis, Lifecode sought to make molecular tumor profiling more accessible and meaningful for developing personalized cancer care strategies.
Keywords: genomic medicine, oncology, molecular diagnostics, next-generation sequencing, clinical laboratory, precision medicine, cancer genomics, data interpretation, SVBio, MedGenome